Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Taro Pharmaceuticals Inc

Home Clinical Trial Sponsors and OrganizationsTaro Pharmaceuticals Inc

Taro Pharmaceuticals Inc

130 East Dr, Brampton, Ontario, Canada$1.6B

Also known as:

taropharma

taro pharmaceutical

taro pharmaceuticals usa

taro pharmaceuticals u.s.a., inc

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

72

0 active

Approvals

300

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

38

52.8%

Phase 2

17

23.6%

Phase 3

9

12.5%

Early Phase 1

7

9.7%

Phase 4

1

1.4%

Trial Status Distribution

Completed

67

93.1%

Terminated

5

6.9%

Clinical Trials

Trials sponsored by this organization (72)

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

Jun 20241,000 participants

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

May 2024382 participants

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

Dec 2023430 participants

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Aug 2023476 participants

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Feb 2023762 participants

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Apr 2021402 participants

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

Sep 2020160 participants

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Aug 2020973 participants

Page 1 of 9

Approvals

Approvals by Agency

FDA

Food and Drug Administration

8

Approvals

CANADA

Health Canada

292

Approvals

Recent Approvals

INFANTS' IBUPROFEN ORAL SUSPENSION

TARO-DICLOFENAC POTASSIUM POWDER FOR ORAL SOLUTION

TARO-METRONIDAZOLE GEL

TARO-METRONIDAZOLE GEL

Glycopyrrolate Oral Solution

Glycopyrrolate Oral Solution

News

No news articles found

On this page

Overview
Clinical Trials72
Approvals300
News

Back to Organizations